Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn’s Disease Phenotypes by Taleban, Sasha et al.
ORIGINAL ARTICLE
Clinical Activity and Quality of Life Indices Are Valid Across
Ulcerative Colitis But Not Crohn’s Disease Phenotypes
Sasha Taleban1,2,10 • Kathleen O. Stewart3 • Darrick K. Li4 • Prashant Singh4 •
Darrell S. Pardi5 • Holly C. Sturgeon3 • Vijay Yajnik3 • Ramnik J. Xavier3,6,7 •
Ashwin N. Ananthakrishnan3,8 • Hamed Khalili3,8,9
Received: 3 February 2016 / Accepted: 20 April 2016 / Published online: 3 May 2016
 Springer Science+Business Media New York 2016
Abstract
Background Clinical activity and quality of life (QOL)
indices assess disease activity in Crohn’s disease (CD) and
ulcerative colitis (UC). However, a paucity of data exists
on the validity of these indices according to disease
characteristics.
Aims To examine the correlation between QOL and clin-
ical activity indices and endoscopic disease activity
according to disease characteristics.
Methods We used a prospective registry to identify CD
and UC patients C18 years old with available information
on Short Inflammatory Bowel Disease Questionnaire
scores (SIBDQ), Harvey–Bradshaw Index (HBI) and sim-
ple endoscopic scores for CD (SES-CD), and Simple
Clinical Colitis Activity Index (SCCAI) and Mayo endo-
scopic score for UC. We used Spearman rank correlations
to calculate correlations between indices and Fisher trans-
formation to compare correlations across disease
characteristics.
Results Among 282 CD patients, we observed poor cor-
relation between clinical activity and QOL indices to
SES-CD with no differences in correlation according to
disease characteristics. Conversely, among 226 UC
patients, clinical activity and QOL had good correlation to
Mayo endoscopic score (r = 0.55 and -0.56, respec-
tively) with better correlations observed with left-sided
versus extensive colitis (r = 0.73 vs. 0.45, p = 0.005)
and shorter duration of disease (r = 0.61 vs. 0.37,
p = 0.04).
Conclusions Our data suggest good correlation between
SCCAI and endoscopic disease activity in UC, particularly
in left-sided disease. Poor correlations between HBI or
SIBDQ and SES-CD appear to be consistent across dif-
ferent disease phenotypes.
Keywords Crohn’s disease  Ulcerative colitis  Quality of
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), collec-
tively known as inflammatory bowel diseases (IBD), are
chronic inflammatory disorders of the gastrointestinal tract
with heterogeneous disease presentation and natural his-
tory. Genome wide association studies have identified over
160 risk loci associated with IBD [1] with distinct genetic
profiles associated with specific IBD phenotypes [2, 3]. In
addition, a number of disease characteristics including
location and behavior, age of onset, and disease duration
are associated with different outcomes and response to
therapy [4–6]. As a result, the management of IBD will
continue to move toward personalized care accounting for
the patient’s unique genetic, clinical, and environmental
background [7].
Persistent, active intestinal inflammation in IBD can
severely impair quality of life and lead to increased hospi-
talization and surgical rates [8, 9]. Ideally the goal of therapy
is deep remission, a combination of endoscopic and clinical
remission, which is associated with improved patient out-
comes [10]. However, endoscopic evaluation is not always
feasible due to its invasive nature, burden to patients,
expense, the risk of complications, and the possibility the
site of active disease may not be reached. As a result,
noninvasive biochemical markers, clinical activity indices
(CAIs), and health-related quality of life (HRQOL) scores
have been used as surrogate markers for disease remission.
While a number of prior studies have demonstrated good
correlations between clinical activity or HRQOL scores and
endoscopic disease activity or inflammatory markers, par-
ticularly in UC [11–13], others have shown fair to poor
correlation in assessing luminal CD [14–16]. The subjective
nature of these indices may explain their poor performance
in some studies, but the degree to which disease hetero-
geneity contributes to this variability is unclear. Although a
unique set of CAIs have been developed for pediatric-onset
IBD [17, 18], similar disease activity indices are used in
adults regardless of age of onset or disease characteristics.
As management of IBD moves toward more personal-
ized care, the validity of current disease activity and
HRQOL indices according to various disease phenotypes
may be critical in development of unique patient-reported
outcome measures. We therefore sought to examine the
validity of current CAI and HRQOL indices as they relate
to endoscopic disease activity according to various disease
phenotypes. We hypothesize that the correlations between
clinical activity or HRQOL scores and endoscopic disease
activity vary according to disease phenotypes.
Materials and Methods
Study Population
Starting in 2004, adult patients, age C18 years, with a
diagnosis of CD or UC were recruited in the Prospective
Registry in IBD Study at Massachusetts General Hospital.
At the time of recruitment, detailed information on disease
characteristics according to the Montreal classification,
lifestyle factors including smoking, body mass index, and
dietary factors, along with other comorbid conditions was
collected. For this study, patients with available clinical
and endoscopic activity indices measured within 1 month
of each other were eligible for primary analyses. The
institutional review board at the Massachusetts General
Hospital approved this study.
Assessment of Clinical and Endoscopic Activity
Indices
In a subset of participants, information on clinical activity
indices—the Harvey–Bradshaw Index (HBI) for CD and
the Simple Clinical Colitis Activity Index (SCCAI) for
UC—and quality of life scores in the form of the Short IBD
Questionnaire (SIBDQ) were collected by research coor-
dinators and further confirmed by the treating gastroen-
terologists. We also retrospectively reviewed endoscopic
examinations performed within 1 month of collection of
clinical activity indices. Two physicians calculated simple
endoscopic scores CD (SES-CD) and Mayo endoscopic
score for UC through review of endoscopic images and
reports.
Assessment of Disease Characteristics and Other
Covariates
Information on age of diagnosis, disease behavior (in-
flammatory, penetrating, stricturing, and perianal disease),
disease location (ileal, colonic, and ileocolonic) for CD or
disease extent (proctitis, left-sided, and extensive) for UC,
previous surgeries for CD, duration of disease, and ever use
of IBD-related medications (steroids and biologics) were
collected and confirmed by review of medical records and
further verified by primary gastroenterologists. The retro-
spective nature of the study prevented accurate assessment
of medication use at the time of clinical activity and quality
of life scoring. In addition, we obtained inflammatory
markers (ESR and CRP) at the time of ascertainment of
clinical activity indices.
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Statistical Analysis
We used Spearman rank correlation to calculate the
relatedness between endoscopic scores and CAI scores,
quality of life (QOL) scores, and CRP and ESR levels. We
defined correlations \0.3 as poor, 0.3–0.7 as good, and
[0.7 as excellent [19]. We also calculated correlations
according to the strata defined by age of diagnosis (17–39,
40–59, C60), disease behavior, disease location or extent,
disease duration (\10 or C10 years), inflammatory
markers (above or below upper the limit of normal), and
surgical history. The stratified correlation coefficients
were then compared using a Fisher r-to-z transformation
[20, 21]. All analyses were conducted using R statistical
software. All p values were two-sided, and the threshold
for statistical significance was set at 0.05. However, we
used a Bonferroni correction to adjust for multiple com-
parisons in analyses that compared correlations according
to disease phenotype with the threshold for statistical
significance set at 0.017.
Results
In total, 282 CD and 226 UC cases with available infor-
mation on endoscopic disease activity and CAIs were eli-
gible for our study (Table 1). The mean age at diagnosis
for CD and UC patients was 30 and 33 years, respectively.
At the time of enrollment, the mean duration of disease for
CD and UC was 9 and 10 years, respectively. Among CD
patients, 72 % had some ileal involvement while 28 % had
isolated colonic disease. Over half of CD participants had
either stricturing or penetrating disease at the time of
enrollment. Among UC patients, 55 % had extensive dis-
ease and just 11 % had proctitis.
In a small validation study (N = 20) of endoscopic
scoring, the inter-observer correlations for Mayo endo-
scopic score and SES-CD were 0.95 and 0.98, respectively.
In addition, in a subset of patients where endoscopic
activity scores also were documented by treating gas-
troenterologists, the correlations between endoscopic
activity scores reported by the treating gastroenterologists
and those reported by the two reviewers were consistently
greater than 0.90.
There was poor correlation between CD simple endo-
scopic score (SES-CD) to SIBDQ (r = -0.16) and HBI
(r = 0.18) and good correlation to ESR (r = 0.30) and
CRP (r = 0.39) (Table 2). We observed good correlation
between the Mayo endoscopic score to SIBDQ
(r = -0.56), SCCAI (r = 0.55), ESR (r = 0.33), and CRP
(r = 0.32).
Disease Location and Behavior
Although the correlations between HBI and SES-CD
appeared to be better in ileal CD compared to colonic or
ileocolonic disease, these comparisons did not reach sta-
tistical significance (Fig. 1). Similarly, the correlations
between SES-CD and SIBDQ according to disease
behavior were not significantly different (Fig. 2). We
observed a similar pattern when comparing SES-CD to
inflammatory markers according to disease location.
We also explored the correlations between CAI or QOL
indices and inflammatory markers to SES-CD according to
disease behavior and observed no significant differences
(Fig. 2). Specifically, the SES-CD had poor correlations with
HBI, SIBDQ, and ESR and good correlations to CRP regardless
of disease behavior. Finally, presence of perianal disease was
not associated with any differences in the correlations between
CAIs, SIBDQ, or ESR/CRP and SES-CD (Fig. 3).
Table 1 Clinical characteristics of participants according to disease
type
Disease type
Crohn’s
disease
N = 283
Ulcerative
colitis
N = 227
Age of diagnosis, mean (std) 30 (11) 34 (14)
Gender, n (%)
Female 166 (59) 97 (43)
Race, n (%)
White 269 (95) 213 (94)
Duration at endoscopy, mean (std) 10 (9) 9 (9)
Location, n (%)
TI 80 (28) N/A
Colon 77 (27) N/A
Ileocolonic 126 (45) N/A
Extent, n (%)
Proctitis N/A 25 (11)
Left-sided N/A 76 (33)
Extensive N/A 126 (56)
Behavior, n (%)
Inflammatory 137 (48) N/A
Stricturing 61 (22) N/A
Penetrating 85 (30) N/A
Perianal 60 (21) N/A
Steroid use, n (%)
Ever 224 (79) 177 (78)
Biologic use, n (%)
Ever 135 (48) 69 (30)
HBI Harvey–Bradshaw Index, SIBDQ Short IBD Questionnaire, CRP
C-reactive protein, ESR erythrocyte sedimentation rate
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In UC, compared to extensive disease, we observed a
better correlation between SCCAI and Mayo endoscopic
score in left-sided colitis (r = 0.73 vs. 0.45, pcomparison =
0.005) (Fig. 4). The correlations between SIBDQ and Mayo
endoscopic score were good across different disease locations
with no statistically significant difference between the cor-
relations. CRP and ESR values appeared to correlate better
with endoscopic score in extensive colitis compared to left-
sided colitis (pcomparison = 0.006 and 0.05, respectively).
Age at Diagnosis
In UC, SCCAI and SIBDQ had good correlations with the
Mayo endoscopic score and were not significantly different
according to age of onset (S1). In CD, we observed con-
sistently poor correlations between clinical and HRQOL to
endoscopic activity indices for patients\60 years old and
good correlation for those C60 years with all comparisons
being statistically insignificant (S1).
Surgical History and Disease Duration
In CD, the correlations between CRP and SES-CD were
good regardless of surgical history (S2). Similarly, corre-
lation between HBI and SIBDQ to SES-CD was poor
regardless of prior surgery (S2).
We also explored whether the correlation between
clinical and endoscopic activity indices differ according to
Table 2 Comparisons of
clinical activity indices, quality
of life scores, and inflammatory
makers with endoscopic activity
indices
Disease type
Crohn’s disease Ulcerative colitis
SES Mayo
SIBDQ, n 207 161
Spearman correlation, rho (p value) 20.16 (0.02) 20.56 (<0.001)
HBI, n 247 N/A
Spearman correlation, rho (p value) 0.18 (0.005)
SCCAI, n 199
Spearman correlation, rho (p value) N/A 0.55 (<0.001)
ESR, n 150 121
Spearman correlation, rho (p value) 0.30 (<0.001) 0.34 (<0.001)
CRP, n 148 124
Spearman correlation, rho (p value) 0.39 (<0.001) 0.46 (<0.001)
Bold values indicate statistical significance (p\ 0.05)
SCCAI Simple Colitis Clinical Activity Index, SIBDQ Short IBD Questionnaire, CRP C-reactive protein,
ESR erythrocyte sedimentation rate
Fig. 1 Correlations between endoscopic activity and indirect disease measures according to Crohn’s disease location
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disease duration (S3). HBI and SIBDQ had poor to good
correlation to SES-CD, while inflammatory markers cor-
related well with SES-CD regardless of disease duration. In
UC, SCCAI correlates better among patients with less than
10 years of disease duration versus longer duration of
disease (r = 0.61 vs. 0.37, pcomparison = 0.04). SIBDQ had
good correlation with endoscopic disease activity, and this
was independent of disease duration. Inflammatory mark-
ers had good correlation with endoscopic disease activity,
irrespective of disease duration.
Fig. 2 Correlations between endoscopic activity and indirect disease measures according to Crohn’s disease behavior
Fig. 3 Correlations between endoscopic activity and indirect disease measures according to presence or absence of perianal disease
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Discussion
In this large cross-sectional study, we show that in CD,
HBI and SIBDQ overall correlate poorly to endoscopic
disease activity regardless of age at diagnosis, disease
location and behavior, duration of disease, and surgical
history. In UC, although there is a good correlation
between SCCAI and SIBDQ to endoscopic disease activity
overall, the correlations appeared to be stronger with left-
sided UC and individuals with shorter duration of disease.
This is the first study to substantiate the use of HRQOL and
clinical activity indices among different IBD phenotypes
according to previously validated endoscopic activity
markers.
Despite the variability of clinical presentations and
outcomes of CD and UC patients, for the most part in our
study the validity of noninvasive measures of disease
activity as they relate to endoscopic disease activity is not
significantly different according to disease behavior and
location and age of onset. This may suggest a couple of
different possibilities. First, clinical activity and HRQOL
scores in IBD may be insufficiently sensitive to distinguish
among different IBD phenotypes. Second, endoscopic
disease activity may not be an accurate measure of com-
plete disease remission, particularly with regard to CD
where active disease may be located beyond the reach of
endoscopic evaluation. In UC, histological remission is
associated with less disease relapse and lower colorectal
cancer risk when compared to endoscopic remission, sug-
gesting that microscopic remission may be a more accurate
predictor of disease outcome [22]. In CD, a transmural
process, mucosal biopsies may not be a sufficient indica-
tion of ‘‘true remission.’’
Traditionally, biochemical parameters and other clinical
activity scores have validated HRQOL and other clinical
activity scores [23, 24], though more recently correlation
with mucosal assessment has become standard [25, 26].
This appears to be a more clinically relevant comparison as
the goal of IBD therapy is mucosal healing, which in turn is
associated with durable remission and decreased risk of
surgery [27]. Consistent with previous work [14, 15, 25], in
our study, SIBDQ and HBI correlated poorly with endo-
scopic disease activity in CD. When examining the rela-
tionship between SIBDQ and endoscopic disease activity,
Casellas et al. [25] reported a correlation of -0.31, similar
to the -0.17 in this study. However, they did not use
validated endoscopic disease scores for either CD or UC.
The SES-CD and the Mayo endoscopic score in UC, used
in the current study, appear to be most reliable measures of
endoscopic disease assessment [28, 29]. In UC, our finding
was consistent with others showing good correlation
between SIBDQ and SCCAI with endoscopic disease
activity [30].
HRQOL scores and CRP have been evaluated according
to various disease characteristics in CD. A European study
of 189 CD patients found no difference between patients
based on the Vienna classification when measured by the
Psychological General Well-Being Index, the EuroQol, and
the IBD Questionnaire [31]. SIBDQ has been measured
according to disease phenotype in patients developing CD
after ileal-pouch anal anastomosis for UC, and no differ-
ence was found between various phenotypes [32]. In CD,
after excluding fibrostenotic disease, elevated CRP levels
have been more commonly associated with colonic and
ileocolonic disease than ileal disease [33], though this
finding has not been consistent in all IBD studies [34].
Additionally, there was no statistically significant differ-
ence between high sensitivity-CRP and disease behavior
[33]. Our study did not show that patient heterogeneity
effected HRQOL and CRP. Additionally, unlike previous
Fig. 4 Correlations between
endoscopic activity and indirect
disease measures according to
ulcerative colitis extent
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analysis, we also evaluated the validity of CRP and
HRQOL scores among older-onset (age C60) disease as
recent data suggests that the elderly may have a less
aggressive disease course [35]. Variations in prior studies
in CRP may be related to the wide ranges of cutoff values
used in IBD [36, 37], and currently there is no accepted
cutoff value. A cutoff value of 10 mg/L has been proposed
for high sensitivity-CRP at diagnosis as a predictor of
disease exacerbation [33].
Recently, the FDA has mandated that clinical trial
endpoints move away from using CAIs and toward endo-
scopic disease assessment and patient-reported outcome
measures [38]. These measures are expected to address the
gaps of previously utilized outcomes and highlight the
patient experience. Although several IBD patient-reported
outcome measures have been proposed [39, 40] or served
as endpoints in clinical trials [10], none have been vali-
dated or correlated with endoscopic disease activity. Kap-
pelmen et al. used the patient-reported outcome measure
information system (PROMIS), developed by the National
Institute of Health, in a longitudinal and cross-sectional
study. In analyzing over 10,000 patients, they found a
statistically significant association between PROMIS and
increasing SIBDQ, short Crohn’s disease activity indices,
and SCCAI. Additionally, short disease duration (\1 year)
was associated with the highest anxiety and depression in
CD and the highest anxiety and fatigue in UC independent
of disease activity. Also, for most outcome measures, age
[60 was associated with better outcomes than patients
between the ages of 18–30 [40]. In this study, often the
differences between outcomes among the different pheno-
types were small suggesting patient-reported outcome
measures may be more sensitive to subtle differences
between patient phenotypes than currently used HRQOL
and disease activity measures.
Various PROMIS scores are associated with disease
activity and QOL scores in IBD [40]. However, since QOL
and disease activity scores often do not correlate well with
endoscopic findings, the accuracy of patient outcome
measures in predicting active intestinal inflammation is
unclear. If further studies reveal little to no correlation
between patient-reported outcomes and mucosal healing,
appropriate medical management in patients will require an
effective balance between these measures.
We acknowledge several limitations. First, our partici-
pants were from a single tertiary IBD center and therefore
our results may not be generalizable to other populations.
However, the characteristics of participants in our study
including age of diagnosis, disease location, and rates of
complications were similar to previous natural history
studies of large population-based cohorts [41, 42]. Second,
the number of participants in some of the categories of
disease location, behavior, and age of diagnosis was small
limiting the precision of our estimates. However, to date
our study represents one of the largest and most compre-
hensive studies attempting to examine the validity of
clinical indices according to various disease characteristics.
In addition, we were able to examine the validity of clinical
indices in older-onset patients (age C60 years), an advan-
tage over prior studies [43]. Further studies should be done
to confirm our findings. Third, over 90 % of patients in the
study were Caucasian, so our results may not extend to
other races or ethnicities. Though a more aggressive dis-
ease course in African-Americans was suggested previ-
ously [44], further analysis has revealed that these
differences were likely due to socioeconomic status and
access to health care [45]. A recent study showed no dif-
ference in perioperative complication rates between His-
panics and non-Hispanics [46]. Furthermore, HRQOL
scores and the HBI in CD have been validated in African-
Americans and remain similar to Caucasians during the
course of disease [45]. Finally, we acknowledge the sub-
jective nature of retrospective evaluation of endoscopic
disease activity. However, in our small validation study,
the correlations between the two reviewers and between the
reviewers and the endoscopists were excellent.
Accurate identification of active intestinal disease in
patients with varying phenotypes is a key to early and
effective therapy. While quality of life and clinical activity
scores reflect endoscopic disease activity in UC, they
perform poorly in CD. The utility of HBI, SCCAI, and
SIBDQ in patients appears to be the same according to
various disease phenotypes. Further studies are necessary
to validate other indices and newly developed IBD patient-
reported outcome measures based on various phenotypes.
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